Orthocell Ltd
ASX:OCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orthocell Ltd
Revenue
Orthocell Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orthocell Ltd
ASX:OCC
|
Revenue
AU$13.9m
|
CAGR 3-Years
69%
|
CAGR 5-Years
67%
|
CAGR 10-Years
25%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Revenue
$65.4m
|
CAGR 3-Years
93%
|
CAGR 5-Years
32%
|
CAGR 10-Years
13%
|
|
|
CSL Ltd
ASX:CSL
|
Revenue
$15.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Revenue
AU$3.4m
|
CAGR 3-Years
153%
|
CAGR 5-Years
189%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Revenue
AU$803.8m
|
CAGR 3-Years
98%
|
CAGR 5-Years
174%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Revenue
AU$24.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
55%
|
CAGR 10-Years
86%
|
|
Orthocell Ltd
Glance View
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.
See Also
What is Orthocell Ltd's Revenue?
Revenue
13.9m
AUD
Based on the financial report for Dec 31, 2025, Orthocell Ltd's Revenue amounts to 13.9m AUD.
What is Orthocell Ltd's Revenue growth rate?
Revenue CAGR 10Y
25%
Over the last year, the Revenue growth was 25%. The average annual Revenue growth rates for Orthocell Ltd have been 69% over the past three years , 67% over the past five years , and 25% over the past ten years .
